which recently won approval for an abuse-deterrent opioid. The opportunity for drugmakers to develop better pain management alternatives is there — 80 million people are prescribed medication to ...

The US regulator has rejected Pain Therapeutics' abuse-deterrent opioid painkiller drug, Remoxy, for the fourth time. In a dreaded complete response letter, the FDA said the benefits listed in the ...

Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, has announced an exclusive partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, a potential ...

Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.

AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl ...

AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl ...

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced ...